Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

NCT04980833 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

PIK3CA-related Overgrowth Spectrum (PROS)

Interventions

DRUG: Alpelisib

Sponsor

Novartis Pharmaceuticals